![Author ORCID: We display the ORCID iD icon alongside authors names on our website to acknowledge that the ORCiD has been authenticated when entered by the user. To view the users ORCiD record click the icon. [opens in a new tab]](https://www.cambridge.org/engage/assets/public/coe/logo/orcid.png){kind=logo}
Abstract
MRTX0902, a novel SOS1 inhibitor, is currently being evaluated in phase I trials for the treatment of cancer. The complexity of the molecule containing a pyrido[3,4-d]pyridazine core and a chiral amine moiety makes it a challenging target to prepare on multi-kilogram scale to support clinical development studies. An efficient and scalable synthesis to the key intermediate, 4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1(2H)-one and a much improved end-game to MRTX0902 was developed.
Supplementary materials
Title
Supporting Information containing NMR spectra
Description
Supporting Information containing NMR spectra (1H and 13C) for the compounds in Scheme 6
Actions
